ER-Positive Breast Cancer

1. Disease Information

Overview. ER-positive breast cancer is invasive (or in situ) breast carcinoma in which tumor cell nuclei express the estrogen receptor alpha (ERα, encoded by ESR1), detected by immunohistochemistry (IHC). By ASCO/CAP 2020 guidance, a tumor is scored ER-positive when ≥1% of tumor nuclei stain, with 1–10% designated "ER-low-positive." ER positivity indicates that tumor growth is at least partly driven by estrogen–ERα signaling and predicts benefit from endocrine (anti-estrogen) therapy. ER+ disease is the largest breast-cancer subgroup — roughly 70–80% of all invasive breast cancers — and most ER+ tumors are also progesterone-receptor (PR)-positive and HER2-negative (the "HR+/HER2−" clinical class), corresponding largely to the luminal A and luminal B intrinsic molecular subtypes (Perou/Sørlie classification; TCGA, PMID:23000897, DOI).

Key identifiers (verified via OLS): - MONDO: MONDO:0006512 — estrogen-receptor positive breast cancer (primary). Related: MONDO:0700079 (hormone receptor-positive breast cancer), MONDO:0021116 (luminal A breast carcinoma), MONDO:0021115 (luminal B breast carcinoma), MONDO:0700078 (triple-positive breast carcinoma). - DOID: DOID:0060075 (estrogen-receptor positive breast cancer); DOID:0070780 (HR+/HER2− breast cancer). - ICD-10: C50.- (malignant neoplasm of breast); ER status captured separately by Z17.0 (estrogen receptor positive status). ICD-11: 2C6- (carcinoma of breast) with molecular-marker extension codes. - ICD-O-3 morphology: most commonly 8500/3 (infiltrating duct carcinoma, NST) and 8520/3 (lobular carcinoma). - NCIT: C53554 (Luminal A), C53555 (Luminal B); estrogen-receptor-positive breast carcinoma is coded in NCIT under the ER-positive neoplasm hierarchy. - MeSH: D001943 (Breast Neoplasms) + "Receptors, Estrogen" (D011960); "Neoplasms, Hormone-Dependent" (D009376). - OMIM: 114480 (Breast cancer, susceptibility) — a phenotype series, not subtype-specific. - Orphanet: breast cancer is generally common (not a rare disease); rare hereditary breast-cancer syndromes carry separate ORPHA codes.

Synonyms / alternative names: ER+ breast cancer; estrogen receptor-positive breast carcinoma; hormone receptor-positive breast cancer (when grouped with PR); hormone-dependent / hormone-responsive breast cancer; luminal breast cancer (approximate molecular equivalent); HR+/HER2− breast cancer (clinical usage).

Data derivation. Disease-level aggregate resource (registries: SEER, national cancer registries; molecular atlases: TCGA, METABRIC). Individual-patient EHR data exist but the canonical characterization is aggregate.

2. Etiology

Primary causal factors. ER+ breast cancer is a multifactorial somatic disease driven by lifetime cumulative estrogen exposure acting on mammary luminal epithelial cells that acquire somatic driver mutations. There is no single causal agent. The dominant mechanistic theme is estrogen-driven proliferation of ERα-expressing luminal cells, on which oncogenic lesions (most commonly PIK3CA, GATA3, TP53, MAP3K1, CDH1, ESR1 amplification) are superimposed (TCGA, PMID:23000897, DOI — "Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence… enrichment of specific mutations in GATA3, PIK3CA and MAP3K1 with the luminal A subtype").

Risk factors — reproductive/hormonal (the ER+-specific axis): - Early menarche, late menopause → longer cumulative ovarian estrogen exposure. - Nulliparity / late first full-term pregnancy (>30 y). - Menopausal hormone therapy (MHT), especially combined estrogen–progestin (Women's Health Initiative; PMID:12117397 — combined MHT increases invasive breast cancer risk). - Obesity in postmenopausal women — adipose aromatase raises circulating/local estrogen; specifically elevates ER+ risk. (Premenopausal obesity is paradoxically weakly protective.) - Alcohol consumption — dose-dependent increase, most consistent for ER+ disease. - Higher endogenous estrogen/androgen levels (EPIC, Endogenous Hormones and Breast Cancer Collaborative Group; PMID:12189224). - Increased mammographic breast density.

Genetic risk factors: - High-penetrance germline: BRCA2 pathogenic variants predispose predominantly to ER+ breast cancer (contrast: BRCA1 → mostly triple-negative). Also PALB2, ATM, CHEK2 — the latter two enrich for ER+ disease. CDH1 (lobular), TP53 (Li-Fraumeni), PTEN. - Polygenic susceptibility: >180 common low-penetrance loci from GWAS; a substantial subset are subtype-specific for ER+ disease (e.g., FGFR2, TOX3/TNRC9, MAP3K1, ESR1 locus, CCND1, 8q24). Breast Cancer Association Consortium (BCAC) GWAS (PMID:29059683). Polygenic risk scores (PRS) predict ER+ risk more strongly than ER− risk.

Protective factors: - Parity and breastfeeding (each reduces risk; breastfeeding disproportionately protects against ER−, but parity protects against ER+ long-term). - Physical activity; maintaining healthy postmenopausal body weight. - Chemoprevention with SERMs/AIs in high-risk women reduces ER+ incidence specifically (tamoxifen, raloxifene — NSABP P-1/STAR; exemestane — MAP.3; anastrozole — IBIS-II). - Genetic protective alleles: protective (risk-reducing) alleles at the same GWAS loci; no single strong Mendelian protective variant.

Gene–environment interactions. PRS × hormonal exposure is broadly multiplicative; MHT and obesity amplify absolute risk most in women with high genetic risk. CYP19A1 (aromatase) and estrogen-metabolism gene variants modulate the estrogen-exposure effect. (CTD/PheGenI/GWAS Catalog.)

3. Phenotypes

ER+ breast cancer's "phenotype" is a combination of clinical/pathological tumor features, laboratory/biomarker abnormalities, and symptoms/signs of local and metastatic disease.

Pathological & molecular phenotype (defining): - Estrogen receptor positivity by IHC (≥1% nuclei). Suggested HPO: HP:0020325 Increased breast-tissue estrogen receptor expression. Frequency: 100% (definitional). - Frequently PR-positive and HER2-negative; typically lower histologic grade, lower Ki-67 proliferation index (especially luminal A), and hormone-dependent (well-differentiated luminal) morphology. - Histology: invasive ductal (NST) most common; invasive lobular carcinoma is strongly enriched (~95% ER+), associated with CDH1 (E-cadherin) loss.

Clinical symptoms/signs (shared with breast cancer generally; HPO terms): - Breast mass / lump — HP:0031093 (Breast mass). Most common presenting sign; frequency very frequent. - Breast neoplasm — HP:0100013. - Nipple discharge / retraction, skin dimpling (peau d'orange), axillary lymphadenopathy — HP:0002716 (Lymphadenopathy). - Metastatic phenotypes (ER+ has a characteristic bone-predominant tropism): bone pain and pathological fracture — HP:0002659/HP:0002754; hepatic metastasis; pulmonary metastasis; and, notably for ER+/lobular, serosal/GI/leptomeningeal spread.

Phenotype characteristics: - Age of onset: predominantly adult / postmenopausal; median age at diagnosis ~62–63 y; ER+ proportion rises with age. - Severity/course: variable. Luminal A → indolent, favorable; luminal B → more proliferative, higher recurrence. Distinctive feature: prolonged risk of late recurrence — ER+ tumors recur at a roughly constant rate for >20 years after diagnosis (EBCTCG, PMID:29860917 context; Pan et al., NEJM 2017, PMID:29131280). - Progression: typically slow-to-intermediate; often relapsing over a long horizon rather than early aggressive relapse.

Quality-of-life impact. Long-term endocrine therapy (5–10 y) causes menopausal symptoms (hot flashes, arthralgia, sexual dysfunction, bone loss) materially affecting QoL and adherence; QoL measured with EORTC QLQ-C30/BR23, FACT-B, EQ-5D.

4. Genetic / Molecular Information

ER+ breast cancer is a somatic (acquired) genomic disease; germline variants contribute susceptibility (Section 2) but the tumors are defined by somatic drivers.

Central gene — ESR1 (ERα): - HGNC:3467, gene symbol ESR1, chromosome 6q25.1; OMIM 133430; UniProt P03372. - ERα is the therapeutic target and dependency. Suggested GO: GO:0030520 (intracellular estrogen receptor signaling pathway); molecular function GO:0030284 (nuclear estrogen receptor activity). - Somatic ESR1 alterations are largely a resistance phenomenon: ESR1 ligand-binding-domain missense mutations (hotspots Y537S, Y537N, Y537C, D538G, also E380Q, L536) produce constitutive, ligand-independent ER activation and confer resistance to estrogen deprivation (aromatase inhibitors). These are rare in primary tumors (<1–3%) but present in ~20–40% of AI-pretreated metastatic tumors (Jeselsohn et al.; review PMID:34392831, DOI — "ESR1 mutations are a common cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase inhibition"*). ESR1 gene fusions and amplification* also occur.

Most frequent somatic driver mutations in ER+/luminal disease (TCGA, PMID:23000897, DOI; METABRIC): - PIK3CA (HGNC:8975; ~40% of HR+ tumors) — activating hotspots E542K, E545K, H1047R → PI3K–AKT–mTOR activation. Actionable (alpelisib). - GATA3 (HGNC:4172) — luminal-lineage transcription factor; enriched in luminal A. - MAP3K1 and MAP2K4 — MAPK pathway; enriched luminal A. - CDH1 (HGNC:1748) — E-cadherin loss defining invasive lobular carcinoma. - TP53 — more frequent in luminal B / higher grade. - AKT1 (E17K), PTEN loss, NF1, RB1 loss (associated with CDK4/6-inhibitor resistance), CCND1 amplification (11q13), FGFR1 amplification (8p11), MYC amplification. - MAP3K1/GATA3/PIK3CA define the "luminal" driver landscape.

Variant classification / origin. Driver events are somatic; classification per AMP/ASCO/CAP oncology tiers (Tier I actionable: PIK3CA, ESR1, AKT1/PTEN, ERBB2 mutations, BRCA1/2). Germline BRCA2/PALB2/ATM/CHEK2 per ACMG. Somatic frequencies documented in COSMIC, cBioPortal (TCGA, METABRIC), ICGC.

Modifier genes. RB1 status and CCNE1 amplification modify CDK4/6-inhibitor response; ESR1 mutation modifies endocrine response; PIK3CA/AKT1/PTEN modify PI3K/AKT-inhibitor benefit.

Epigenetics. ER+ tumors show characteristic DNA-methylation programs (TCGA CIMP-like luminal cluster); ER target-gene enhancer reprogramming, FOXA1-dependent pioneer chromatin remodeling, and methylation-mediated silencing (e.g., of ESR1 itself in a minority → ER-loss/resistance). Histone modifications and enhancer hijacking underpin acquired endocrine resistance.

Chromosomal features. Recurrent CNAs: 1q gain, 16q loss (hallmark of low-grade luminal / lobular), 8q24 (MYC) gain, 11q13 (CCND1) amplification, 8p11 (FGFR1) amplification. Luminal A is relatively genomically quiet; luminal B is more aneuploid.

5. Environmental Information

• Endocrine-disrupting / hormonal exposures: exogenous estrogens (combined MHT), and debated roles for environmental xenoestrogens.
• Alcohol (dose-dependent, ER+-specific signal), postmenopausal obesity/adiposity (aromatase-driven local estrogen), physical inactivity, Western/high-caloric diet.
• Ionizing radiation (therapeutic chest RT in youth, e.g., Hodgkin lymphoma; atomic-bomb survivor data) increases overall breast-cancer risk.
• Infectious agents: None established. ER+ breast cancer is not an infectious/oncoviral disease (unlike some cancers). Not applicable.

6. Mechanism / Pathophysiology

Core causal chain (upstream → downstream):

1. Estrogen (17β-estradiol; CHEBI:16469) binds ERα in luminal mammary epithelial cells → receptor dimerization, nuclear translocation, binding to estrogen response elements (EREs). Pioneer factor FOXA1 and cofactor GATA3 license ER chromatin binding.
2. ER-driven transcription activates proliferation and survival genes — CCND1 (cyclin D1), MYC, TFF1/pS2, GREB1, PGR (progesterone receptor, itself an ER target — hence PR positivity is a marker of intact ER signaling).
3. Cyclin D1–CDK4/6 activation → RB phosphorylation → E2F release → G1/S cell-cycle progression. This is the proliferative engine and the rationale for CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib).
4. Cross-talk with growth-factor/PI3K–AKT–mTOR and MAPK pathways amplifies and can bypass ER signaling; PIK3CA/AKT1 activation and PTEN loss drive both proliferation and endocrine resistance.
5. Clinical manifestation: clonal expansion → invasive carcinoma → lymphatic/hematogenous dissemination (bone-tropic).

Molecular pathways (KEGG/Reactome): Estrogen signaling (KEGG hsa04915; Reactome "ESR-mediated signaling" R-HSA-8939211); PI3K–AKT (hsa04151); cell cycle (hsa04110); MAPK (hsa04010); mTOR.

Cellular processes (GO): GO:0030520 (intracellular estrogen receptor signaling pathway); GO:0008283 (cell population proliferation); GO:0000082 (G1/S transition of mitotic cell cycle); GO:0043066 (negative regulation of apoptosis). Cell type of origin (CL): luminal epithelial cell of mammary gland — CL:0002326; broadly CL:0000066 (epithelial cell).

Protein dysfunction. ERα gain-of-function via LBD mutation (constitutive activity independent of ligand). PI3Kα (p110α) hyperactivation. Cyclin D1 overexpression. RB1 loss (loss of function). E-cadherin (CDH1) loss → discohesive lobular growth.

Metabolic changes. ER+ tumors are relatively less glycolytic than basal tumors; estrogen regulates lipid and glucose metabolism; endocrine resistance can involve metabolic reprogramming and lipid-metabolism/cholesterol (27-hydroxycholesterol as an endogenous SERM) contributions.

Immune involvement. ER+ (luminal) tumors are typically "immune cold" — low tumor-infiltrating lymphocytes and low PD-L1 relative to TNBC — explaining limited single-agent immunotherapy benefit in most HR+ disease.

Molecular profiling. Transcriptomic signatures define prognosis and chemo-benefit: PAM50 (luminal A vs B, ROR score), Oncotype DX 21-gene Recurrence Score, MammaPrint 70-gene, EndoPredict, Breast Cancer Index. Proteomic (RPPA in TCGA), and single-cell/spatial studies reveal luminal-hormone-sensing vs luminal-progenitor cell states and microenvironmental heterogeneity.

Suggested GO/CL summary for KB: biological processes GO:0030520, GO:0000082, GO:0008283; cell type CL:0002326 (luminal epithelial cell of mammary gland).

7. Anatomical Structures Affected

• Primary organ: breast / mammary gland — UBERON:0000310 (breast); UBERON:0001911 (mammary gland). Ductal-lobular epithelium — UBERON:0002518 (mammary duct region).
• Tissue/cell level: mammary luminal epithelium (glandular epithelial cells lining ducts/lobules). CL:0002326 (luminal epithelial cell of mammary gland).
• Regional spread: axillary lymph nodes — UBERON:0002439 (axillary lymph node).
• Metastatic sites (organ-tropism, characteristic for ER+): bone (UBERON:0002481; most common ER+ metastatic site), liver (UBERON:0002107), lung (UBERON:0002048), and less commonly brain; ER+ lobular carcinoma uniquely spreads to peritoneum/GI tract, ovary, and leptomeninges.
• Subcellular (GO cellular component): nucleus (GO:0005634) — site of ER transcriptional activity; also cytoplasm/plasma membrane (non-genomic ER signaling).
• Lateralization: unilateral typical; bilateral/contralateral risk elevated (metachronous), especially with germline predisposition and lobular histology.

8. Temporal Development

• Onset: adult; predominantly peri-/postmenopausal; insidious (asymptomatic screen-detected mass or symptomatic lump). Median diagnosis ~62 y.
• Staging: AJCC 8th edition anatomic + prognostic staging incorporates ER/PR/HER2 and grade (ER positivity down-stages prognostic group). Stages 0 (DCIS)/I–IV.
• Progression rate: generally slow (luminal A) to intermediate (luminal B).
• Course pattern: the hallmark of ER+ disease is a persistent, roughly constant late-recurrence hazard extending beyond 10–20 years — distinct from ER− disease, whose recurrence risk peaks early (~2–3 y) then falls. This underpins extended endocrine therapy (up to 10 y). (Pan et al., NEJM 2017, PMID:29131280; EBCTCG analyses.)
• Remission: treatment-induced; early-stage ER+ is often curable, but micrometastatic dormancy explains late relapse.
• Critical intervention windows: adjuvant endocrine therapy years 0–10; ovarian suppression in high-risk premenopausal women; the window before acquired ESR1/PI3K resistance in the metastatic setting.

9. Inheritance and Population

Epidemiology (According to PubMed — ACS Breast Cancer Statistics 2024, Giaquinto et al., PMID:39352042, DOI): - Breast cancer is the most common invasive cancer in women. US incidence rose ~1% annually 2012–2021, "largely confined to localized-stage and hormone receptor-positive disease", with a steeper rise in women <50 (1.4%/y vs 0.7%/y). - Overall breast-cancer death rate fell 44% (1989–2022), ≈517,900 fewer deaths — reflecting screening and effective endocrine/systemic therapy. - ER+ constitutes ~70–80% of invasive breast cancers (rising proportion in older women). - Disparities: "Black women have 38% higher mortality than White women despite 5% lower incidence… Black women have the lowest survival for every breast cancer subtype and stage except localized disease." Fastest incidence rise in Asian American/Pacific Islander women.

Global: breast cancer ~2.3 million new cases/year worldwide (GLOBOCAN 2020/2022, IARC); leading cause of cancer death in women globally.

Inheritance. ER+ breast cancer is not Mendelian; it is multifactorial/polygenic with a minority (~5–10%) attributable to high-penetrance germline predisposition (BRCA2 > BRCA1 for ER+, PALB2, ATM, CHEK2, CDH1, TP53, PTEN). Penetrance is age-dependent and gene/variant-specific (e.g., BRCA2 ~45–55% lifetime breast-cancer risk). Founder effects: BRCA1/2 Ashkenazi Jewish founder alleles (185delAG, 5382insC, 6174delT); Icelandic BRCA2 999del5. Anticipation/germline mosaicism: not applicable to this somatic subtype.

Demographics. Sex ratio: overwhelmingly female (~99%); male breast cancer is disproportionately ER+ (>90%). Age distribution skews older; ER+ fraction increases with age.

10. Diagnostics

Core pathological diagnosis: - Biopsy + histopathology (core-needle or excisional) with invasive carcinoma confirmation. - ER IHC (nuclear staining, ≥1% positive = ER+; ASCO/CAP 2020) — the defining test. Companion PR IHC and HER2 IHC/ISH; Ki-67 proliferation index (luminal A vs B surrogate). LOINC/SNOMED-coded pathology. - Grade (Nottingham/Elston-Ellis).

Biomarkers / molecular assays: - Multigene prognostic/predictive assays: Oncotype DX 21-gene Recurrence Score, MammaPrint 70-gene, PAM50/Prosigna ROR, EndoPredict, Breast Cancer Index (predicts extended-endocrine benefit). - Genomic testing (metastatic): PIK3CA (tissue or ctDNA — companion diagnostic for alpelisib), ESR1 mutation (ctDNA/liquid biopsy — companion for elacestrant), AKT1/PTEN (capivasertib), BRCA1/2 germline (PARP inhibitors), ERBB2 mutations, MSI/TMB, NTRK. - Liquid biopsy (ctDNA): increasingly used to detect ESR1/PIK3CA mutations and monitor resistance (SERD selection).

Imaging: mammography (screening/diagnostic), breast ultrasound, breast MRI (high-risk/lobular). Staging: CT, bone scan, FDG-PET/CT (note ER+/lobular can be FDG-low); FES-PET (18F-fluoroestradiol) images ER expression functionally.

Genetic testing. Germline multigene panel (BRCA1/2, PALB2, ATM, CHEK2, CDH1, TP53, PTEN) per NCCN criteria; cascade testing of relatives. WES/WGS not routine clinically.

Clinical criteria / differential. Differential: benign breast disease (fibroadenoma, cyst), other subtypes (TNBC, HER2+), phyllodes, lymphoma; ER-low-positive tumors behave biologically more like ER− and warrant caution.

Screening. Population mammographic screening (USPSTF now recommends biennial screening starting age 40); high-risk MRI; genetic/carrier screening in familial cases.

11. Outcome / Prognosis

• Prognosis is comparatively favorable among breast-cancer subtypes; ER positivity is an independent favorable prognostic factor and a predictive marker of endocrine benefit. 5-year relative survival for localized ER+/HR+ disease exceeds 90–99%; regional ~86%; distant/metastatic ~30% (5-yr) but improving with CDK4/6 inhibitors.
• Distinctive late-recurrence risk: durable relapse hazard for >20 years (Pan et al., PMID:29131280) — cumulative distant recurrence continues even for node-negative disease.
• Metastatic ER+ is treatable but generally incurable; median overall survival in first-line endocrine + CDK4/6-inhibitor era now ~5+ years for many patients (MONALEESA/PALOMA/MONARCH OS data).

Prognostic factors: tumor stage/nodal burden, grade, Ki-67/proliferation, PR status (PR-negativity worse), genomic risk score, luminal A vs B, and (metastatic) acquired ESR1/PIK3CA/RB1 alterations. Predictive biomarkers: PIK3CA, ESR1, AKT1/PTEN, BRCA1/2, HER2-low status.

Morbidity: treatment-related (endocrine-therapy menopausal symptoms, arthralgia, osteoporosis, thromboembolism/endometrial risk with tamoxifen; CDK4/6-inhibitor neutropenia/diarrhea). Metastatic morbidity is bone-dominant (fractures, hypercalcemia, cord compression).

12. Treatment

ER+ breast cancer is the paradigm of targeted endocrine therapy. Suggested MAXO terms noted inline.

A. Endocrine (anti-estrogen) therapy — backbone (MAXO: pharmacotherapy; NCIT:C15986): - Selective estrogen receptor modulators (SERMs): tamoxifen (CHEBI:41774) — pre- and postmenopausal; 5–10 y adjuvant. Extended 10-y tamoxifen (ATLAS/aTTom) reduces late recurrence. - Aromatase inhibitors (AIs): anastrozole, letrozole, exemestane — postmenopausal (block peripheral estrogen synthesis; CYP19A1 target). Superior to tamoxifen in postmenopausal adjuvant (EBCTCG AI meta-analysis). - Ovarian function suppression (OFS): GnRH agonists (goserelin/leuprolide) — high-risk premenopausal, combined with AI or tamoxifen (SOFT/TEXT trials established OFS + exemestane benefit in high-risk young women). - Selective estrogen receptor degraders (SERDs): fulvestrant (injectable; CHEBI:31638) and the first oral SERD, elacestrant — FDA-approved Jan 2023 for ESR1-mutant HR+/HER2− metastatic BC after prior endocrine therapy (EMERALD trial; PMID:37314500, DOI — "the first orally bioavailable SERD approved by the FDA… whose tumors harbor an ESR1 missense mutation").

B. Targeted agents added to endocrine therapy: - CDK4/6 inhibitors — palbociclib, ribociclib, abemaciclib. Standard first-line partner with AI/fulvestrant in metastatic HR+/HER2−; roughly double PFS and improve OS (MONALEESA, PALOMA, MONARCH). In adjuvant high-risk early disease, abemaciclib improved invasive disease-free survival (monarchE; PMID:32954927, DOI — "the first CDK4/6 inhibitor to demonstrate a significant improvement in IDFS… HR 0.75… 2-year IDFS 92.2% vs 88.7%"); ribociclib (NATALEE) subsequently added a broader adjuvant indication. - PI3K inhibitor — alpelisib (+ fulvestrant) for PIK3CA-mutant disease (SOLAR-1; PMID:31091374, DOI — PFS 11.0 vs 5.7 months, HR 0.65 in PIK3CA-mutated cohort; key toxicity hyperglycemia). - AKT inhibitor — capivasertib (+ fulvestrant) after AI ± CDK4/6-inhibitor progression, benefit in overall and AKT-pathway-altered (PIK3CA/AKT1/PTEN) populations (CAPItello-291; PMID:37256976, DOI — PFS 7.3 vs 3.1 months, HR 0.50 in altered population). - mTOR inhibitor — everolimus (+ exemestane) after AI resistance (BOLERO-2). - PARP inhibitors — olaparib, talazoparib for germline BRCA1/2-mutant HR+ disease (OlympiA adjuvant; OlympiAD metastatic).

C. Antibody–drug conjugates (later-line): - Trastuzumab deruxtecan for HER2-low (IHC 1+/2+ ISH−) HR+ metastatic disease (DESTINY-Breast04; PMID:35665782, DOI — HR+ cohort PFS 10.1 vs 5.4 months, OS 23.9 vs 17.5 months; watch interstitial lung disease). - Sacituzumab govitecan (Trop-2 ADC) in endocrine-refractory HR+ metastatic disease (TROPiCS-02).

D. Chemotherapy — reserved for high genomic-risk early disease and endocrine-refractory/visceral-crisis metastatic disease. Genomic assays spare most low-risk patients: TAILORx (PMID:29860917, DOI) showed endocrine therapy noninferior to chemoendocrine therapy for node-negative, RS 11–25 (with some benefit in women ≤50, RS 16–25); RxPONDER (PMID:34914339, DOI) showed node-positive (1–3), RS ≤25 postmenopausal women derive no chemo benefit, whereas premenopausal women do (HR 0.60).

E. Local therapy: surgery (breast-conserving surgery or mastectomy; MAXO:0000004/NCIT surgical procedure) + sentinel/axillary node evaluation; radiotherapy (MAXO:0000014) as indicated.

F. Supportive/preventive adjuncts: bone-targeted agents (bisphosphonates/denosumab) for bone metastases and to reduce recurrence (adjuvant zoledronic acid in postmenopausal women, EBCTCG).

Pharmacogenomics: CYP2D6 poor-metabolizer status reduces conversion of tamoxifen to active endoxifen (CPIC guidance; clinical impact debated). PIK3CA/ESR1/BRCA genotype-guided therapy selection is now standard (My Cancer Genome, OncoKB, CIViC).

13. Prevention

• Primary prevention / chemoprevention (ER+-specific): SERMs tamoxifen, raloxifene (NSABP P-1, STAR) and AIs exemestane (MAP.3), anastrozole (IBIS-II) reduce ER+ breast-cancer incidence ~50–65% in high-risk women (USPSTF endorses risk-reducing medication for high-risk women). MAXO: pharmacotherapy / chemoprevention.
• Risk-reducing surgery: bilateral risk-reducing mastectomy and/or salpingo-oophorectomy in high-penetrance carriers (BRCA1/2, etc.); oophorectomy reduces estrogen exposure.
• Lifestyle: weight control, alcohol reduction, physical activity, limiting combined MHT.
• Secondary prevention: population mammographic screening (USPSTF biennial from 40), supplemental MRI in high-risk; risk stratification with models (Tyrer-Cuzick/IBIS, Gail, BOADICEA/CanRisk incorporating PRS).
• Genetic counseling / cascade testing for hereditary predisposition; PGD/prenatal options for high-penetrance syndromes.
• Immunization / public-health / environmental interventions: not applicable (non-infectious).

14. Other Species / Natural Disease

• Taxonomy: primary human disease — Homo sapiens (NCBITaxon:9606). Naturally occurring mammary carcinoma also in domestic dog (Canis lupus familiaris, NCBITaxon:9615), domestic cat (Felis catus, NCBITaxon:9685), and lab rodents.
• Comparative/veterinary: Canine mammary tumors are a leading canine neoplasm; a subset are ER-positive and hormone-dependent (ovariohysterectomy before first estrus is strongly protective), providing a spontaneous large-animal comparative model. Feline mammary carcinoma tends to be more aggressive and frequently ER-negative/HER2-driven (models aggressive human disease). (OMIA; comparative oncology literature.)
• Evolutionary conservation: ESR1/estrogen signaling and mammary developmental programs are conserved across mammals; orthologs — mouse Esr1 (NCBI Gene 13982), rat Esr1 (Gene 24890), dog ESR1 (Gene 403640).
• Transmission / zoonosis: not applicable.

15. Model Organisms

• Cell lines (in vitro; workhorses of ER+ research): MCF-7 (Cellosaurus CVCL_0031; ER+ luminal, estrogen-responsive), T-47D (CVCL_0553; ER+/PR+), ZR-75-1 (CVCL_0588), BT-474 (ER+/HER2+), and CAMA-1. Derivatives model endocrine resistance (long-term estrogen-deprived MCF-7, tamoxifen-resistant lines) and ESR1-mutant knock-in lines (Y537S, D538G).
• Organoids / PDX: patient-derived ER+ organoids and PDX models (though ER+ PDX engraftment is historically harder than TNBC); estrogen-supplementation-dependent PDXs. iPSC/3D models emerging.
• Genetically engineered mouse models (GEMMs): ER+ luminal tumorigenesis is harder to model than basal disease. Relevant models: MMTV-PyMT (luminal-like progression, though ER expression declines with progression), Pik3ca^H1047R conditional models, Esr1-driven and Wnt1 models; hormone (estrogen-pellet)-dependent models. Model limitation: mouse mammary tumors poorly recapitulate the sustained ERα-dependence and estrogen-driven growth of human luminal disease — a recognized translational gap (relevant HUMAN_MODEL_MISMATCH framing for KB).
• Induced models: chemical carcinogen (DMBA/MNU) rat mammary carcinomas are classically ER-positive and hormone-responsive — historically important for endocrine-therapy and chemoprevention testing (e.g., tamoxifen, AIs). Rat (Rattus norvegicus) NMU model is a strong ER+ phenotype-recapitulating system.
• Applications: endocrine-therapy mechanism/resistance, CDK4/6 and PI3K/AKT combination testing, ESR1-mutation biology, chemoprevention.
• Resources: Cellosaurus, ATCC, MGI, RGD, DepMap (dependency/CRISPR screens: ESR1, FOXA1, GATA3, CDK4/6 dependencies in luminal lines), Alliance of Genome Resources.

Curation Notes & Ontology Summary (for dismech entry)

Highest-value, verified PMIDs for evidence items (all abstracts retrieved and quotes confirmed via PubMed):

Additional canonical PMIDs cited from domain knowledge (verify snippets before use as evidence): 29131280 (Pan et al., 20-year recurrence risk, NEJM 2017); 12117397 (WHI combined MHT); 12189224 (endogenous hormones meta-analysis); 29059683 (BCAC GWAS, 65 new loci).

Important caveats for the KB curator

1. Verify every snippet against the fetched cache (just fetch-reference PMID:… → just validate-references). Quotes above are transcribed from PubMed abstracts but must pass the exact-substring check. The abstracts for SOLAR-1 (PMID:31091374) rendered with dropped gene symbols in the PubMed feed (e.g., "-mutated" for PIK3CA-mutated); re-fetch and quote a clean substring.
2. This is a subtype/molecular-class entry, not a Mendelian disorder — omit inapplicable template fields (anticipation, mosaicism, single-gene knockout recapitulation) or record them explicitly as not applicable.
3. HER2-low and ER-low-positive are evolving biomarker categories — flag as active-research (KNOWLEDGE_GAP).
4. Consider conforms_to links to relevant dismech cancer-hallmark modules — especially sustaining_proliferative_signaling (ER→cyclin D1→CDK4/6), evading_growth_suppressors (RB axis / CDK4/6-inhibitor target), and resisting_cell_death — and the endocrine-therapy drug-mechanism pattern (ER as target of SERM/SERD/AI).

Disorder

• Name: ER-Positive Breast Cancer
• Category:
• Existing deep-research providers: falcon
• Existing evidence reference count in YAML: 16

Key Pathophysiology Nodes

• Estrogen Receptor Activation
• Estrogen-Driven Transcription
• Cell Cycle Progression
• Deep research literature mapping

Citation Inventory (for evidence mapping)

• DOI:10.33590/emjoncol/njqz9723
• DOI:10.3390/ijms26073438
• DOI:10.3390/jcm13123611
• DOI:10.61882/tcr.202501.01.05

Pathophysiology description (narrative)

ER+ breast cancer is driven by estrogen receptor alpha (ERα; ESR1)–dependent transcriptional programs primed by pioneer factors (FOXA1, GATA3) and modulated by oncogenic crosstalk (PI3K/AKT/mTOR, RTKs such as FGFR/HER2) and the tumor microenvironment. Under selective pressure from aromatase inhibitors (AIs) and other endocrine therapies, tumors frequently acquire ESR1 ligand-binding domain (LBD) mutations or rearrangements that sustain ligand-independent ER signaling and promote endocrine resistance; combination strategies targeting PI3K/AKT/mTOR and cell cycle (CDK4/6) have become foundational, with biomarker-guided escalation to oral SERDs (e.g., elacestrant) and AKT inhibition (capivasertib) in defined molecular subsets (ESR1-mutated; PIK3CA/AKT1/PTEN-altered). High-level summaries of these mechanisms and therapeutic linkages are consolidated in the embedded table artifact. (ferro2024noveltreatmentstrategies pages 23-24, santangelo2025secondlinestrategiesto pages 7-7, ferrari2025molecularmechanismsand pages 1-2)

Table: Table summarizing core ER-positive breast cancer mechanisms, key genes/proteins with suggested GO pathway terms, linked therapeutic classes (examples), and supporting evidence from recent reviews and studies (2023–2025 reviews cited). This consolidates mechanistic-to-clinical links useful for knowledge-base annotation and therapeutic decision contexts.

Required Information

1. Core Pathophysiology

• Primary mechanisms
• ER/ESR1 signaling is central; endocrine pressure selects ESR1 LBD mutations (e.g., Y537S, D538G) that stabilize agonist conformations and drive AI resistance, often retaining susceptibility to SERDs though polyclonality can limit response. Quote: “Mutations in ESR1 contribute to ET resistance by mediating ligand-independent ER signaling… ESR1-mutant cancers are often AI-resistant but remain susceptible to SERDs.” (Journal of Clinical Medicine 2024; review of EMERALD and targeted strategies). URL: https://doi.org/10.3390/jcm13123611 (June 2024) (ferro2024noveltreatmentstrategies pages 23-24)
• PI3K/AKT/mTOR activation (PIK3CA mutation, PTEN loss, AKT1 activation) promotes survival and endocrine resistance; clinical actionability is established for alpelisib (PIK3CA-mutant) and capivasertib (PIK3CA/AKT1/PTEN-altered) in combination with fulvestrant (CAPItello‑291). (santangelo2025secondlinestrategiesto pages 7-7, ferro2024noveltreatmentstrategies pages 23-24)
• CDK4/6 pathway cooperates with ER to drive G1/S; CDK4/6 inhibitors with ET are standard, yet resistance emerges via RB1 loss, cyclin E/CDK2 upshift, PI3K/FGFR signaling, and microenvironmental adaptation. (ferro2024noveltreatmentstrategies pages 23-24)
• Growth factor crosstalk: FGFR1 amplification/overexpression and HER2 pathway activity can reprogram ER signaling and mediate resistance, supporting rationale for FGFR/HER2-directed approaches in select contexts. (ramezani2025mechanismsofendocrine pages 13-15, ferrari2025molecularmechanismsand pages 1-2)
• Epigenetic/chromatin remodeling remodels the ER cistrome (e.g., chromatin modifiers, pioneer factor dynamics), contributing to endocrine resistance and CDK4/6 resistance; integrative reviews highlight chromatin/epigenetic lesions as recurrent features. (ramezani2025mechanismsofendocrine pages 11-13, ramezani2025mechanismsofendocrine pages 13-15)
• Tumor microenvironment (TME) and immune contexture (CAF-derived cytokines, immune suppression) influence ER expression/function and resistance trajectories; biomarker use remains limited beyond PIK3CA and ESR1 but microenvironment signatures are emerging. (ramezani2025mechanismsofendocrine pages 13-15, ferrari2025molecularmechanismsand pages 1-2)
• Dysregulated pathways
• Steroid hormone receptor transcription (ESR1); PI3K/AKT/mTOR; RTK signaling (FGFR/HER2); cell cycle/CDKs; NF-κB/chemokine axes; epigenetic remodeling. (ramezani2025mechanismsofendocrine pages 13-15)
• Cellular processes affected
• Proliferation (G1/S transition), survival signaling, chromatin accessibility and enhancer usage, metabolic rewiring, immune evasion via stromal/immune reprogramming. (ramezani2025mechanismsofendocrine pages 13-15)

2. Key Molecular Players

• Genes/Proteins (HGNC)
• ESR1 (ERα); FOXA1; GATA3; PIK3CA; AKT1; PTEN; MTOR; CCND1/CDK4/CDK6; RB1; FGFR1–4; ERBB2 (HER2); chromatin modifiers (e.g., ARID1A, KMT2C). (ferro2024noveltreatmentstrategies pages 23-24, ramezani2025mechanismsofendocrine pages 13-15, ferrari2025molecularmechanismsand pages 1-2)
• Chemical Entities (CHEBI; drugs)
• SERMs (tamoxifen), SERDs (fulvestrant; oral SERD elacestrant), CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib), PI3K inhibitor alpelisib, AKT inhibitor capivasertib, mTOR inhibitor everolimus; HER2‑targeted ADCs in HER2‑low contexts (trastuzumab deruxtecan). (ferro2024noveltreatmentstrategies pages 23-24, santangelo2025secondlinestrategiesto pages 7-7)
• Cell Types (CL)
• Luminal epithelial tumor cells; cancer-associated fibroblasts (CAFs); tumor-infiltrating lymphocytes (TILs) including CD8+ T cells; macrophages; endothelial cells. (ramezani2025mechanismsofendocrine pages 13-15, ferrari2025molecularmechanismsand pages 1-2)
• Anatomical Locations (UBERON)
• Mammary gland (UBERON:0001911); common metastatic sites—bone (UBERON:0002481), liver (UBERON:0002107), lung (UBERON:0002048). (ferro2024noveltreatmentstrategies pages 23-24)

3. Biological Processes (GO annotation)

• Steroid hormone receptor signaling (GO:0030520); transcription by RNA polymerase II (GO:0006351); chromatin remodeling (GO:0006338); PI3K/AKT signaling (GO:0014065); mTOR signaling (GO:0031929); G1/S transition (GO:0044843); receptor tyrosine kinase signaling (GO:0007169); immune response (GO:0006955); cell–cell signaling (GO:0007267). (ramezani2025mechanismsofendocrine pages 13-15, ferrari2025molecularmechanismsand pages 1-2)

4. Cellular Components

• Nuclear chromatin (GO:0000790); ER transcriptional complexes at enhancers; plasma membrane (RTKs); cytosol (PI3K/AKT/mTOR); extracellular space (cytokines, growth factors). (ramezani2025mechanismsofendocrine pages 13-15)

5. Disease Progression

• Sequence of events
• Initiation and growth via ER-dependent luminal programs; endocrine therapy imposes selective pressure; acquisition of ESR1 mutations/fusions and activation of compensatory PI3K/AKT/mTOR and RTKs foster acquired resistance; additional cell-cycle and epigenetic reprogramming consolidate progression; metastatic colonization shaped by microenvironmental niches (e.g., bone). (ferro2024noveltreatmentstrategies pages 23-24, ramezani2025mechanismsofendocrine pages 13-15)
• Stages/phases
• Endocrine-sensitive phase (robust CDK4/6+ET benefit), emerging resistance (ctDNA-detectable ESR1 mutations), clinically resistant phase with actionable pathway alterations guiding SERD or AKT/PI3K/mTOR targeting. (santangelo2025secondlinestrategiesto pages 7-7, ferro2024noveltreatmentstrategies pages 23-24)

6. Phenotypic Manifestations

• Clinical phenotypes
• Recurrence after adjuvant ET; metastatic progression (bone-predominant pattern common in ER+ disease); endocrine-refractory disease with reduced ET response durations. (ferro2024noveltreatmentstrategies pages 23-24)
• Relation to mechanisms
• ESR1-mutant tumors are AI-resistant but may benefit from SERDs; PIK3CA/AKT1/PTEN-altered tumors benefit from AKT inhibition (capivasertib) with fulvestrant; PI3Kα-mutant tumors benefit from alpelisib+fulvestrant; RTK/FGFR-driven reprogramming aligns with endocrine resistance. (santangelo2025secondlinestrategiesto pages 7-7, ferro2024noveltreatmentstrategies pages 23-24)

Current applications and real-world implementations

• Biomarker testing and therapy selection
• Routine testing in advanced HR+/HER2− disease increasingly includes ESR1 (ctDNA or tissue) and PIK3CA/AKT1/PTEN. Expert summary: “few biomarkers are currently used in routine clinical practice beyond PIK3CA mutation and, increasingly, ESR1 mutation in the metastatic setting.” (Nov 2025; URL: https://doi.org/10.61882/tcr.202501.01.05) (ramezani2025mechanismsofendocrine pages 13-15)
• Trials and approvals
• EMERALD: oral SERD elacestrant improved PFS vs standard ET in ESR1-mutated ER+/HER2− MBC, with larger benefit after ≥12 months of prior ET+CDK4/6i exposure; real-world PFS ~8–9 months, ~5.2 months with coexistent PIK3CA mutations. (EMJ Oncology 2025 review; summarizes 2024 data). URL: https://doi.org/10.33590/emjoncol/NJQZ9723 (May 2025) (santangelo2025secondlinestrategiesto pages 1-3)
• CAPItello‑291: capivasertib+fulvestrant improved PFS in PIK3CA/AKT1/PTEN‑altered tumors after AI±CDK4/6i; incorporated into approvals (2023–2024). (EMJ Oncology 2025 review). URL: https://doi.org/10.33590/emjoncol/NJQZ9723 (May 2025) (santangelo2025secondlinestrategiesto pages 7-7)
• Imaging
• 18F‑FES PET can assess ER expression heterogeneity and predict ET responsiveness; used for staging/recurrence assessment and therapy selection in ER+ breast cancer. (summarized in 2024–2025 sources). (santangelo2025secondlinestrategiesto pages 1-3)

Expert opinions and analysis (authoritative sources; quotes)

• On ESR1 mutations and SERDs: “Mutations in ESR1 contribute to ET resistance by mediating ligand-independent ER signaling… [they] are often AI-resistant but remain susceptible to SERDs.” (Journal of Clinical Medicine review, June 2024). URL: https://doi.org/10.3390/jcm13123611 (ferro2024noveltreatmentstrategies pages 23-24)
• On breadth of mechanisms and need for composite biomarkers: “endocrine resistance is multifactorial and dynamic… few biomarkers are currently used in routine clinical practice beyond PIK3CA mutation and, increasingly, ESR1 mutation in the metastatic setting.” (The Cancer Review, Nov 2025). URL: https://doi.org/10.61882/tcr.202501.01.05 (ramezani2025mechanismsofendocrine pages 13-15)

Relevant statistics and data

• Prevalence/actionability
• ESR1 mutations arise commonly at progression in metastatic settings under AI pressure; biomarker-guided oral SERD therapy (elacestrant) shows PFS benefit in ESR1-mutated tumors in EMERALD; capivasertib+fulvestrant shows PFS benefit in PIK3CA/AKT1/PTEN-altered disease (CAPItello‑291; 2023–2024 practice updates). (santangelo2025secondlinestrategiesto pages 7-7, santangelo2025secondlinestrategiesto pages 1-3)

Structured ontology annotations

• Gene/protein annotations (HGNC): ESR1; FOXA1; GATA3; PIK3CA; AKT1; PTEN; MTOR; CCND1; CDK4; CDK6; RB1; FGFR1; ERBB2; ARID1A; KMT2C. (ramezani2025mechanismsofendocrine pages 13-15)
• GO biological processes: GO:0030520; GO:0006351; GO:0006338; GO:0014065; GO:0031929; GO:0044843; GO:0007169; GO:0006955; GO:0007267. (ramezani2025mechanismsofendocrine pages 13-15)
• Cell types (CL): luminal epithelial cells; CAFs; CD8+ T cells; macrophages. (ramezani2025mechanismsofendocrine pages 13-15)
• Anatomical (UBERON): breast, bone, liver, lung. (ferro2024noveltreatmentstrategies pages 23-24)
• Chemical entities (CHEBI): elacestrant; fulvestrant; tamoxifen; alpelisib; capivasertib; everolimus; CDK4/6 inhibitors. (santangelo2025secondlinestrategiesto pages 7-7, ferro2024noveltreatmentstrategies pages 23-24)

Evidence items with PMIDs/DOIs/URLs and dates

• Ferro et al., Novel treatment strategies for HR+ HER2− MBC. Journal of Clinical Medicine, June 2024. DOI: 10.3390/jcm13123611. URL: https://doi.org/10.3390/jcm13123611 (mechanisms, SERDs, CDK4/6, PI3K/AKT/mTOR; includes EMERALD context). (ferro2024noveltreatmentstrategies pages 23-24)
• Santangelo, Second-line strategies… EMJ Oncology, May 2025; synthesizes 2024 data for elacestrant (EMERALD) and capivasertib (CAPItello‑291). DOI: 10.33590/emjoncol/njqz9723. URL: https://doi.org/10.33590/emjoncol/njqz9723 (santangelo2025secondlinestrategiesto pages 7-7, santangelo2025secondlinestrategiesto pages 1-3)
• Ramezani & Soheili Azad, Mechanisms of endocrine resistance… The Cancer Review, Nov 2025 (integrated genomic/translational review—epigenetics, microenvironment, biomarkers). DOI: 10.61882/tcr.202501.01.05. URL: https://doi.org/10.61882/tcr.202501.01.05 (ramezani2025mechanismsofendocrine pages 13-15, ramezani2025mechanismsofendocrine pages 17-18)
• Ferrari et al., Molecular mechanisms and strategies… IJMS, Apr 2025 (overview of ESR1 genetics, microenvironment, combinations). DOI: 10.3390/ijms26073438. URL: https://doi.org/10.3390/ijms26073438 (ferrari2025molecularmechanismsand pages 1-2)

Limitations and scope note: While the narrative prioritizes 2023–2024 topics and clinical practices (SERDs, CDK4/6, PI3K/AKT/mTOR, imaging), several integrative reviews summarizing 2024 data were published in early 2025; these were included when they synthesized 2023–2024 primary evidence. Citations track to available context IDs above.

References

1. (ferro2024noveltreatmentstrategies pages 23-24): Antonella Ferro, Michela Campora, Alessia Caldara, Delia De Lisi, Martina Lorenzi, Sara Monteverdi, Raluca Mihai, Alessandra Bisio, Mariachiara Dipasquale, Orazio Caffo, and Yari Ciribilli. Novel treatment strategies for hormone receptor (hr)-positive, her2-negative metastatic breast cancer. Journal of Clinical Medicine, 13:3611, Jun 2024. URL: https://doi.org/10.3390/jcm13123611, doi:10.3390/jcm13123611. This article has 23 citations and is from a poor quality or predatory journal.

2. (santangelo2025secondlinestrategiesto pages 7-7): Samantha Santangelo. Second-line strategies to overcome resistance to oestrogen therapy in patients with er+/her2- metastatic breast cancer: a year in review. EMJ Oncology, pages 2-9, May 2025. URL: https://doi.org/10.33590/emjoncol/njqz9723, doi:10.33590/emjoncol/njqz9723. This article has 0 citations.

3. (ferrari2025molecularmechanismsand pages 1-2): Paola Ferrari, Maria Luisa Schiavone, Cristian Scatena, and Andrea Nicolini. Molecular mechanisms and therapeutic strategies to overcome resistance to endocrine therapy and cdk4/6 inhibitors in advanced er+/her2− breast cancer. International Journal of Molecular Sciences, Apr 2025. URL: https://doi.org/10.3390/ijms26073438, doi:10.3390/ijms26073438. This article has 7 citations and is from a poor quality or predatory journal.

4. (ramezani2025mechanismsofendocrine pages 13-15): Sepehr Ramezani and Faezeh soheili azad. Mechanisms of endocrine resistance in hormone receptor–positive breast cancer: an integrated genomic and translational review. The Cancer Review, 1:56-73, Nov 2025. URL: https://doi.org/10.61882/tcr.202501.01.05, doi:10.61882/tcr.202501.01.05. This article has 0 citations.

5. (ferro2024noveltreatmentstrategies pages 26-27): Antonella Ferro, Michela Campora, Alessia Caldara, Delia De Lisi, Martina Lorenzi, Sara Monteverdi, Raluca Mihai, Alessandra Bisio, Mariachiara Dipasquale, Orazio Caffo, and Yari Ciribilli. Novel treatment strategies for hormone receptor (hr)-positive, her2-negative metastatic breast cancer. Journal of Clinical Medicine, 13:3611, Jun 2024. URL: https://doi.org/10.3390/jcm13123611, doi:10.3390/jcm13123611. This article has 23 citations and is from a poor quality or predatory journal.

6. (ramezani2025mechanismsofendocrine pages 11-13): Sepehr Ramezani and Faezeh soheili azad. Mechanisms of endocrine resistance in hormone receptor–positive breast cancer: an integrated genomic and translational review. The Cancer Review, 1:56-73, Nov 2025. URL: https://doi.org/10.61882/tcr.202501.01.05, doi:10.61882/tcr.202501.01.05. This article has 0 citations.

7. (santangelo2025secondlinestrategiesto pages 1-3): Samantha Santangelo. Second-line strategies to overcome resistance to oestrogen therapy in patients with er+/her2- metastatic breast cancer: a year in review. EMJ Oncology, pages 2-9, May 2025. URL: https://doi.org/10.33590/emjoncol/njqz9723, doi:10.33590/emjoncol/njqz9723. This article has 0 citations.

8. (ramezani2025mechanismsofendocrine pages 17-18): Sepehr Ramezani and Faezeh soheili azad. Mechanisms of endocrine resistance in hormone receptor–positive breast cancer: an integrated genomic and translational review. The Cancer Review, 1:56-73, Nov 2025. URL: https://doi.org/10.61882/tcr.202501.01.05, doi:10.61882/tcr.202501.01.05. This article has 0 citations.